MODERN STRATEGIES TO PREVENT CORONARY SEQUELAE AND STROKE IN HYPERTENSIVE PATIENTS DIFFER FROM THE JNC-V CONSENSUS GUIDELINES

被引:30
作者
TOBIAN, L [1 ]
BRUNNER, HR [1 ]
COHN, JN [1 ]
GAVRAS, H [1 ]
LARAGH, JH [1 ]
MATERSON, BJ [1 ]
WEBER, MA [1 ]
机构
[1] CUMC,NEW YORK HOSP,CTR CARDIOVASC & HYPERTENS,NEW YORK,NY 10021
关键词
HYPERTENSION TREATMENT; GOVERNMENT GUIDELINES; JNC V; BETA-BLOCKERS; DIURETICS; FIRST-LINE THERAPY;
D O I
10.1093/ajh/7.10.859
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
In recent years, government agencies of many countries have established consensus guidelines for the evaluation and treatment of hypertension. Once published, guidelines tend to be perceived as directives by a variety of health care providers. Unfortunately, these guidelines often do not reflect the practices of most hypertension experts. This report summarizes the opinions of seven hypertension experts concerning the impact of ''official'' guidelines on clinical practice. In addition, the individual therapeutic recommendations of these panel members are summarized. Their different treatment strategies reflect the diversity of first rate treatment plans that aim to reduce the cardiovascular sequelae in individual patients with essential hypertension. Most importantly, not one of these seven treatment strategies followed the ''preferred'' treatment of the U.S, guidelines, which recommend diuretics and beta-blockers as first-line therapy. The present authors approach the treatment of hypertension as a means to reduce cardiovascular events, Thus, reduction of blood pressure is not the most important therapeutic endpoint. The panel believes that whereas many different drugs can produce effective blood pressure reduction, the modern primary goal of antihypertensive drug therapy is to select a regimen most likely to prolong the quality and duration of life. In real terms, this means that the primary goal of treatment is the prevention of the major vascular sequelae of hypertension (heart attack, ventricular remodeling, hypertrophy, heart failure, and stroke) that shorten useful life. There are a number of effective hypertensive treatments, which can be selected based on individual patient requirements. However, many consensus guidelines do not allow the flexibility required to optimize individual patient treatment. As a result, health care providers should not feel compelled to regard the preferences of ''official'' guidelines as the best, modern, state-of-the-art therapy for an individual patient. All seven experts who are deeply involved in the daily care of patients preferred drugs other than beta-blockers and diuretics (the Joint National Committee [JNC] choices) for first-line therapy of hypertension.
引用
收藏
页码:859 / 872
页数:14
相关论文
共 71 条
[1]  
Chassin M.R., Standards of care in medicine, Inquiry, 25, pp. 437-453, (1988)
[2]  
Leape L.L., Practice guidelines and standards: An overview, Qual Rev Bull, 16, pp. 42-49, (1990)
[3]  
The President's Health Security Plan: The Clinton Blueprint, pp. 111-122, (1993)
[4]  
Sever P., Beevers G., Bulpitt C., Et al., Management guidelines in essential hypertension: Report of the Second Working Party of the British Hypertension Society, Brmed J, 306, pp. 983-987, (1993)
[5]  
The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V), Arch Intern Med, 153, pp. 154-183, (1993)
[6]  
Guidelines for the management of mild hypertension: Memorandum from a World Health Organization/International Society of Hypertension meeting, Hypertension, 22, pp. 392-403, (1993)
[7]  
Jackson R., Barham P., Bills J., Et al., Management of raised blood pressure in New Zealand: A discussion document, Brmed J, 307, pp. 107-110, (1993)
[8]  
Swales J.D., Guidelines on guidelines, J Hypertens, 11, pp. 899-903, (1993)
[9]  
The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions, N Engl J Med, 327, pp. 685-691, (1992)
[10]  
Pfeffer M.A., Braunwald E., Moye L., Et al., On behalf of the SAVE Investigators: Effects of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction, N Engl J Med, 327, pp. 669-677, (1992)